Although PD‐1/PD‐L1 blockade has achieved revolutionary success in cancer treatment over the last decade, only 15%–20% of HCC patients showed durable clinical benefits and objective remissions, and novel therapeutic strategies are needed to improve the clinical management [34, 35, 36]. Here, CD274 is linked to cancer.